HighPoint Advisor Group LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,054 shares of the life sciences company’s stock, valued at approximately $638,000.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ILMN. Dimensional Fund Advisors LP lifted its holdings in Illumina by 3.5% during the first quarter. Dimensional Fund Advisors LP now owns 264,925 shares of the life sciences company’s stock valued at $45,211,000 after purchasing an additional 9,017 shares during the last quarter. KCG Holdings Inc. purchased a new stake in Illumina during the first quarter valued at about $290,000. Tudor Investment Corp ET AL purchased a new stake in Illumina during the first quarter valued at about $289,000. NN Investment Partners Holdings N.V. lifted its holdings in Illumina by 11.3% during the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after purchasing an additional 100 shares during the last quarter. Finally, State of Alaska Department of Revenue purchased a new stake in Illumina during the second quarter valued at about $345,000. 92.70% of the stock is currently owned by institutional investors and hedge funds.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded up $0.20 during midday trading on Tuesday, reaching $209.14. 372,800 shares of the company’s stock were exchanged, compared to its average volume of 967,756. Illumina, Inc. has a twelve month low of $119.37 and a twelve month high of $214.50. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. The company has a market capitalization of $30,505.24, a PE ratio of 61.09, a P/E/G ratio of 3.45 and a beta of 0.74.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. During the same period last year, the business earned $0.97 earnings per share. The business’s quarterly revenue was up 17.6% on a year-over-year basis. sell-side analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current year.
Several equities research analysts have commented on ILMN shares. Barclays PLC upped their price objective on shares of Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 price target on the stock in a report on Friday, October 27th. Canaccord Genuity reissued a “buy” rating and issued a $230.00 price target (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. BidaskClub downgraded shares of Illumina from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 25th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $226.00 price target (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $200.88.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/11/14/highpoint-advisor-group-llc-acquires-new-holdings-in-illumina-inc-ilmn.html.
In other news, Director Jay T. Flatley sold 22,540 shares of the stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the completion of the sale, the director now owns 539,176 shares of the company’s stock, valued at $105,252,546.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Mostafa Ronaghi sold 20,000 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $210.00, for a total value of $4,200,000.00. Following the sale, the senior vice president now directly owns 86,725 shares of the company’s stock, valued at approximately $18,212,250. The disclosure for this sale can be found here. In the last three months, insiders have sold 167,964 shares of company stock valued at $34,559,469. Insiders own 1.60% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.